Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Imaging technologies may give answers in cancer trials

Advances in imaging technologies could provide knowledge about the pharmacodynamics and pharmacokinetics of new cancer drugs in clinical trials, according to a recent review article (Journal of the National Cancer Institute 2006;98:580).

The authors focus on two such technologies — magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) — because they are increasingly available and offer superior functional and metabolic understanding compared with many other imaging tools.

Paul Workman, lead author and chairman of Cancer Research UK’s pharmacodynamic and pharmacokinetic technologies advisory committee, said that technologies such as MRS and PET could improve how drugs are monitored and reduce the need for invasive procedures such as biopsies.

Citation: The Pharmaceutical Journal URI: 10021706

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.